Browsing Tag
PYRUKYND
3 posts
Agios shakes up sickle cell therapy landscape with mixed but promising RISE UP phase 3 data for mitapivat
Find out how Agios’ mixed but promising RISE UP phase 3 data for mitapivat could reshape sickle cell treatment and influence regulatory decisions.
Agios Pharmaceuticals’ mitapivat meets primary endpoint in Phase 3 thalassemia trial
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation,…
Agios Pharmaceuticals gets PYRUKYND FDA approval for hemolytic anemia
Agios Pharmaceuticals has secured approval for PYRUKYND (mitapivat) from the US Food and Drug Administration (FDA) for the…